Literature DB >> 30507747

Classification of amyloid PET images using novel features for early diagnosis of Alzheimer's disease and mild cognitive impairment conversion.

Yu Yan1, Edward Somer2, Vicente Grau1.   

Abstract

BACKGROUND: New PET tracers could have a substantial impact on the early diagnosis of Alzheimer's disease (AD), particularly if they are accompanied by optimised image analysis and machine learning methods. Fractal dimension (FD) analysis, a measure of shape complexity, has been proven useful in MRI but its application to fluorine-18 amyloid PET has not yet been demonstrated. Shannon entropy (SE) has also been proposed as a measure of image complexity in DTI imaging, but it is not yet widely used in radiology.
MATERIALS AND METHODS: In this study, one volumetric FD method and one volumetric SE method were applied to fluorine-18-flutemetamol and fluorine-18-florbetapir 3D amyloid images from 65 and 281 participants, respectively, including healthy volunteers, and patients with probable Alzheimer's disease (pAD) or mild cognitive impairment (MCI).
RESULTS: The group average FD of white matter surface and SE of white matter volume for healthy volunteers were higher than for pAD patients. Both FD and SE are effective in the identification of MCI patients who progress to pAD during the 2-year follow-up (ground truth). Finally, we developed a support vector machine multimodal classification framework using both PET and MRI features, which showed higher accuracy compared to traditional standard uptake value ratio or using PET alone. The classification accuracy for flutemetamol and florbetapir is 88.9 and 83.3%, respectively, for MCI progression, which is competitive with existing literature.
CONCLUSION: The results presented in this study demonstrate the potential of FD and SE methods for the analysis of brain PET scans in early AD diagnosis and in the prediction of MCI-AD conversion.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30507747     DOI: 10.1097/MNM.0000000000000953

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  SPON1 Can Reduce Amyloid Beta and Reverse Cognitive Impairment and Memory Dysfunction in Alzheimer's Disease Mouse Model.

Authors:  Soo Yong Park; Joo Yeong Kang; Taehee Lee; Donggyu Nam; Chang-Jin Jeon; Jeong Beom Kim
Journal:  Cells       Date:  2020-05-21       Impact factor: 6.600

Review 2.  Imaging biomarkers in neurodegeneration: current and future practices.

Authors:  Peter N E Young; Mar Estarellas; Emma Coomans; Meera Srikrishna; Helen Beaumont; Anne Maass; Ashwin V Venkataraman; Rikki Lissaman; Daniel Jiménez; Matthew J Betts; Eimear McGlinchey; David Berron; Antoinette O'Connor; Nick C Fox; Joana B Pereira; William Jagust; Stephen F Carter; Ross W Paterson; Michael Schöll
Journal:  Alzheimers Res Ther       Date:  2020-04-27       Impact factor: 6.982

3.  Immune abnormalities and differential gene expression in the hippocampus and peripheral blood of patients with Alzheimer's disease.

Authors:  Xiaonan Wang; Di Wang; Fei Su; Chunmei Li; Min Chen
Journal:  Ann Transl Med       Date:  2022-01

Review 4.  The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence.

Authors:  Anuschka Silva-Spínola; Inês Baldeiras; Joel P Arrais; Isabel Santana
Journal:  Biomedicines       Date:  2022-01-29

5.  Regional Brain Fusion: Graph Convolutional Network for Alzheimer's Disease Prediction and Analysis.

Authors:  Wenchao Li; Jiaqi Zhao; Chenyu Shen; Jingwen Zhang; Ji Hu; Mang Xiao; Jiyong Zhang; Minghan Chen
Journal:  Front Neuroinform       Date:  2022-04-29       Impact factor: 4.081

6.  Differential Expression of mRNAs in Peripheral Blood Related to Prodrome and Progression of Alzheimer's Disease.

Authors:  Weishuang Xue; Jinwei Li; Kailei Fu; Weiyu Teng
Journal:  Biomed Res Int       Date:  2020-10-31       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.